Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Rush University Medical Center

1653 W. Congress Pkwy, Chicago, IL 60612

Rush University Medical Center is a not-for-profit, 664-bed academic medical center in Chicago. It is nationally and internationally known for many specialties of care, areas of research and its new medical hospital building, the Tower. Rush is consistently ranked among the nation’s top hospitals in U.S. News & World Report.

Our medical staff of more than 800 represents virtually every specialty and subspecialty of care. Known for extraordinary collaboration, physicians at Rush bring to patients the value of many minds by working in teams.

Rush University Medical Center nurses, who are also highly specialized, are on the frontline of our efforts to provide quality care. They have earned Magnet status — the highest recognition in nursing — four consecutive times for making outstanding nursing care the standard at the Medical Center.

Our 376-bed Tower hospital building opened in 2012 as part of the Medical Center’s major campus renovation. Rush’s commitment to sustainability innovation earned the Tower LEED Gold certification.

Website: https://www.rush.edu/services/cancer-center

Contact:
Rush University Cancer Clinical Trial Office (CCTO)
(312)-CANCER-1 or Cancer_Studies@rush.edu

Trials at this location:

HCRN GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

Status: Open to Accrual
Read More

HCRN LUN18-335

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Status: Open to Accrual
Read More

HCRN LUN18-357

Induction durvalumab followed by chemoradiation and consolidation durvalumab (MEDI4736) for stage III non-small cell lung cancer

Status: Open to Accrual
Read More

HCRN GU17-289

A Phase II Randomized, Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289)

Status: Closed to Accrual
Read More

HCRN LUN17-321

A Phase II Study of Concurrent Chemoradiation Plus Durvalumab (MEDI4736) Followed by Surgery Followed by Adjuvant Durvalumab (MEDI4736) in Medically Operable Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Status: Closed to Accrual
Read More